Option FanaticOptions, stock, futures, and system trading, backtesting, money management, and much more!

CBRE Stock Study (5-13-24)

Posted by on May 31, 2024 at 07:09 | Last modified: May 13, 2024 11:53

I recently did a stock study on CBRE Group, Inc. (CBRE, $90.22). Previous studies can be seen here, here, here, and here.

Value Line writes:

     > CBRE Group, Inc. is a worldwide commercial real estate
     > firm, offering services to occupiers, owners, lenders, and
     > investors in the office, retail, industrial, and multi-family
     > segments of the market. Provides facilities management,
     > leasing, property sales, mortgage origination, investment
     > management, and valuation services.

Over the last 10 years, this large-size company has grown sales and earnings at annualized rates of 15.7% and 12.9%, respectively. Visual inspection is mediocre. Revenue is mostly up with a dip in ’20 while EPS dips in ’20, ’22 and ’23 making for somewhat of a cyclical look.

Over the past decade, PTPM leads peer and industry averages despite trending down from 8.6% (’14) to 4.0% (’23) with a last-5-year mean of 5.6%. ROE leads peer and industry averages despite declining from 22.5% (’14) to 12.5% (’23) with a last-5-year mean of 18.7% (downside outlier of 11.4% in ’20 excluded). Debt-to-Capital is lower than peers and about even with the industry while falling from 51.8% (’14) to 36.9% (’23) with a last-5-year mean of 35.3%.

Value Line gives a Financial Strength rating of B++ along with Interest Coverage over 25.0. M* assigns a “Standard” rating for Capital Allocation and reports Quick Ratio of 1.1.

With regard to sales growth:

I am forecasting below the range at 4.0% per year.

With regard to EPS growth:

I am forecasting below the long-term-estimate range (mean of three: 14.4%) at 10.0% per year. I will use ’23 EPS of $3.15/share as the initial value rather than 2024 Q1 EPS of $3.21 (annualized).

My Forecast High P/E is 19.0. Over the past decade, high P/E ranges from 16.3 in ’18 and ’19 to 30.5 in ’20 with a last-5-year mean of 24.6 and last-5-year-mean average P/E of 19.3. I am near the bottom of the range (only ’18 and ’19 are lower).

My Forecast Low P/E is 12.0. Over the past decade, low P/E ranges from 10.0 in ’19 to 20.5 in ’23 with a last-5-year mean of 14.0. I am near the bottom of the range [only ’19 and ’21 (10.9) are lower].

My Low Stock Price Forecast (LSPF) is $64.60. The default $47.20 based on $3.15/share initial value seems unreasonably low at 58.1% off the previous close. I will therefore use the 52-week low instead: 28.4% less than the previous close.

These inputs land CBRE in the SELL zone with a U/D ratio of 0. Total Annualized Return (TAR) is 0.2%.

PAR (using Forecast Average—not High—P/E) is an unacceptable -3.3%. If a healthy margin of safety (MOS) anchors this study, then I can proceed based on TAR but even that is much lower than the current yield on T-bills.

To assess MOS, I compare my inputs with those of Member Sentiment (MS). Based on only eight studies done in the past 90 days (my study along with four outliers excluded), averages (lower of mean/median) for projected sales growth, projected EPS growth, Forecast High P/E, and Forecast Low P/E are 8.0%, 14.2%, 23.5, and 13.9, respectively. I am lower across the board. Value Line projects a future average annual P/E of 15.0 that is lower than MS (18.7) and lower than mine (15.5).

MS high / low EPS are $6.20 / $3.17 versus my $5.07 / $3.15 (per share). My high EPS is less due to a lower growth rate. Value Line’s high EPS of $7.25 is greater than both.

MS LSPF of $60.80 implies a Forecast Low P/E of 19.2 versus the above-stated 13.9. MS LSPF is 38.0% greater than the default $3.17/share * 13.9 = $44.06, which results in more aggressive zoning. MS LSPF is 5.9% less than mine, however.

TAR (over 15.0% preferred) is much less than MS 9.8%. Despite the very small MS sample, I am forecasting conservatively at every turn. I believe MOS to be robust in the current study.

With regard to valuation, PEG is 2.6 per my projected P/E: overvalued. Relative Value [(current P/E) / 5-year-mean average P/E] also looks overvalued at 1.5.

What a difference nine months makes in terms of analyst estimates! Mixed growth/contraction numbers have given way to solid growth prospects.

Unfortunately, EPS has fallen in each of the last two years leaving those higher growth estimates to compound on a much lower base. I think this is why future appreciation potential is sapped. Perhaps the fate of a cyclical company is never having a compelling stock study. For me, this underlines the importance of “up, straight, and parallel” so as to not have the risk of historical inconsistency threatening whenever I look at the visual inspection.

CBRE is a BUY under $71/share. The stock needs to fall about 50% in order to satisfy my personal TAR criterion.

Full disclaimer: I currently own shares. While I’m tempted to hold for the impressive future growth estimates, I should probably sell for a small gain and look for something that more easily clears the barbed wire fence.

Categories: BetterInvesting® | Comments (0) | Permalink

EPAM Stock Study (5-10-24)

Posted by on May 29, 2024 at 07:22 | Last modified: May 10, 2024 10:13

I recently did a stock study on EPAM Systems Inc. (EPAM) with a closing price of $181.93. The previous study is here.

M* writes:

     > EPAM Systems is a global IT services firm that offers
     > platform engineering, software development, and consulting
     > services. EPAM’s largest market is North America, which
     > represents approximately 60% of revenues. Offerings span
     > assisting companies with new technologies, such as
     > artificial intelligence, virtual reality, and robotics.

The stock fell ~27% on May 9 after lower revenue and EPS guidance. I expect analyst estimates will be modified accordingly over the next week(s), but I wanted to do an immediate First Cut to see how it looks through my conservative lenses.

Over the past 10 years, this medium-size company has grown sales and EPS at annualized rates of 24.6% and 24.9%, respectively. Lines are mostly up, straight, and parallel except for a sales dip in ’23 and EPS dips in ’17, ’22, and ’23.

Over the past decade, PTPM appears to be above peer averages (website not displaying peer or industry lines) while ranging from 10.5% in ’22 to 14.2% in ’20 and ’21 with a last-5-year mean of 12.7%. ROE also appears to lead peer averages while ranging from 7.1% in ’17 to 19.8% in ’21 with a last-5-year mean of 16.1%. Debt-to-Capital appears well below peer averages with a last-5-year mean of 9.1%.

EPAM has a Quick Ratio of 4.5, which is one of the highest I have ever seen. All debt is long-term with no interest due [leases perhaps]. I’m surprised to see Value Line only give a B++ grade for Financial Strength. M* gives a “Standard” rating for Capital Allocation and categorizes the company with a “Narrow” economic moat.

With regard to sales growth:

I am forecasting below the range at 2.0% per year.

With regard to EPS growth:

My 3.0% forecast is at the bottom of the [very large] long-term range. Mean (n = 4) is currently 11.2%, but I expect Value Line and Seeking Alpha to decrease. Initial value is ’23 EPS of $7.06/share.

My Forecast High P/E is 33.0. Over the past decade, high P/E ranges from 34.0 in ’18 to 95.3 in ’22 with a last-5-year mean of 70.3 and a last-5-year-mean average P/E of 47.1. I am below the range.

My Forecast Low P/E is 20.0. Over the past decade, low P/E ranges from 21.0 in ’14 to 48.0 in ’17 with a last-5-year mean of 28.8 (last-10-year median 27.5). I am below the range.

My Low Stock Price Forecast (LSPF) of $141.20 is default based on the initial value. This is 22.4% less than the previous close and 21.7% less than the 52-week low.

These inputs land EPAM in the HOLD zone with a U/D ratio of 2.2. Total Annualized Return (TAR) is 8.2%.

PAR (using Forecast Average—not High—P/E) is 3.6%, which is less than the current yield on T-bills. If a healthy margin of safety (MOS) anchors this study, then I can proceed based on TAR instead.

To assess MOS, I compare my inputs with those of Member Sentiment (MS). Based on only 26 [nine months ago this number was 152] studies done in the past 90 days (my study and 8 outliers excluded), averages (lower of mean/median) for projected sales growth, projected EPS growth, Forecast High P/E, and Forecast Low P/E are 10.0%, 9.3%, 42.0, and 26.6, respectively. I am lower across the board. Value Line projects a future average annual P/E of 23.0, which is much lower than MS (34.3) and lower than mine (26.5).

MS high / low EPS are $11.37 / $7.07 versus my $8.18 / $7.06 (per share). My high EPS is lower due to a lower growth rate. Value Line has high EPS at $15.50: much higher than both. As mentioned, I expect this to come down.

MS LSPF of $185.00 (INVALID) implies a Forecast Low P/E of 26.2 vs. the above-stated 26.6. MS LSPF is 1.6% less than the default $7.07/share x 26.6 = $188.06 (also INVALID), which results in more conservative zoning. MS LSPF is 31.0% greater than mine, however.

TAR (over 15.0% preferred) is much less than MS 13.2%. Despite the small MS sample size, I think I did a pretty good job of using conservative judgments. I believe MOS to be robust in the current study.

With regard to valuation, PEG is 6.0 and 8.3 per Zacks and my projected P/E: both significantly overvalued due to low growth-rate denominators. Relative Value [(current P/E) / 5-year-mean average P/E] is cheap at 0.52.

As mentioned at the top, it will take some time for analysts to digest the earnings announcement and modify estimates. After such a sharp selloff, though, I wanted to see if we might have a screaming BUY right now. M* maintains an updated 4-star rating while Value Line and CFRA updates will be forthcoming. I certainly don’t hear any screaming. In fact, I’m not sure I hear anything at all.

EPAM is a BUY under $173/share. With a forecast high price ~$270, my personal TAR criterion won’t be satisfied until ~$135.

Categories: BetterInvesting® | Comments (0) | Permalink

MDT Stock Study (5-9-24)

Posted by on May 27, 2024 at 07:17 | Last modified: May 9, 2024 12:01

I recently did a stock study on Medtronic PLC with a previous closing price of $81.55.

M* writes:

     > One of the largest medical-device companies, Medtronic develops
     > and manufactures therapeutic medical devices for chronic diseases.
     > Its portfolio includes pacemakers, defibrillators, heart valves,
     > stents, insulin pumps, spinal fixation devices, neurovascular
     > products, advanced energy, and surgical tools. The company
     > markets its products to healthcare institutions and physicians
     > in the United States and overseas. Foreign sales account for
     > roughly 50% of the company’s total sales.

Over the last 10 years, this large-size company has posted annualized growth of 5.5% and 2.3% for sales and EPS, respectively. Sales dips in ’20 and ’23 while EPS dips in ’15, ’18, ’21, and ’23 (FY ends 4/30 and references to year on the website and Value Line need to be incremented by one). As a result, lines are generally up but not very straight or parallel. While visual inspection could certainly be worse, I’m not surprised to see MDT missing from the First Cut database until now.

Over the past decade, PTPM leads peer and industry averages while ranging from 12.9% in ’21 to 21.8% in ’14 with a last-5-year mean of 15.7%. ROE slightly trails peer and industry averages while declining from 15.6% in ’14 to 7.3% in ’23 with a last-5-year mean of 8.4%. Debt-to-Capital is less than peer and industry averages while falling from 37.9% (’14) to 32.1% (’23) with a last-5-year mean of 32.8%.

Current Ratio is 1.5 and Interest Coverage is 8.9. M* rates “Standard” for Capital Allocation while Value Line gives a Financial Strength rating of A+.

With regard to sales growth:

I am forecasting below the range at 3.0% per year.

With regard to EPS growth:

I am forecasting below the long-term-estimate range (mean of five: 6.5%) at 3.0% per year. I will use ’23 EPS of $2.82 as the initial value rather than 2024 Q3 $3.14/share (annualized).

My Forecast High P/E is 29.0. Over the past decade, high P/E trends up from 20.8 (’14) to 37.7 (’23) with a last-5-year mean of 37.5 and a last-5-year-mean average P/E of 31.7. My forecast is near the bottom of the range (only ’14 is lower).

My Forecast Low P/E is 22.0. Over the past decade, low P/E trends up from 15.4 (’14) to 26.9 (’23) with a last-5-year mean of 25.9 and last-10-year median of 24.1. My forecast is near the bottom of the range [only ’14 and ’20 (20.4) are lower].

My Low Stock Price Forecast (LSPF) of $62.00 is default based on $2.82/share initial value. This is 24.0% less than previous close and 9.9% less than the 52-week low.

Over the past decade, Payout Ratio (PR) ranges from 37.1% (’14) to 96.5% (’23) with a last-5-year mean of 74.2%. I am forecasting below the range at 37.0%.

These inputs land MDT in the HOLD zone with a U/D ratio of 0.7. Total Annualized Return (TAR) is 4.3%.

PAR (using Forecast Average—not High—P/E) of 1.9% is less than the current yield on T-bills. If a healthy margin of safety (MOS) anchors this study, then I can proceed based on TAR instead (still less than the risk-free rate).

To assess MOS, I compare my inputs with those of Member Sentiment (MS). Based on only 85 studies done in the past 90 days (my study and 21 other outliers excluded), averages (lower of mean/median) for projected sales growth, projected EPS growth, Forecast High P/E, Forecast Low P/E, and PR are 4.0%, 6.0%, 32.0, 25.2, and 72.9%, respectively. I am lower across the board. Value Line projects a future average annual P/E of 18.0 that is much lower than MS (28.6) and mine (25.5).

MS high / low EPS are $4.29 / $3.12 versus my $3.27 / $2.82 (per share). My high EPS is lower due to a lower growth rate. Value Line’s high EPS of $7.85 is much greater than both (thereby offsetting the 18.0 from above).

MS LSPF of $68.80 implies a Forecast Low P/E of 22.1 versus the above-stated 25.2. MS LSPF is 12.5% less than the default $3.12/share x 25.2 = $78.62 resulting in more conservative zoning. MS LSPF is 11.0% greater than mine, however.

TAR (over 15.0% preferred) is much less than MS 12.4%. I believe MOS to be robust in the current study.

With regard to valuation, PEG is 2.7 and 8.4 per Zacks and my projected P/E, respectively: the latter significantly overvalued due to my low growth rate. Relative Value [(current P/E) / 5-year-mean average P/E] is slightly undervalued at 0.82.

Some may argue this study to be unreasonably harsh. I give a haircut by using initial value at the bottom of a sinusoidal historical EPS uptrend and by lowballing a historically uptrending P/E range. I also minimize PR, which hurts a stock that pays an above-average yield (TAR would be 5.6% for 74.0% PR). In case of overkill, next time I might consider taking initial value at the trendline (unless cyclical forces have already done so).

Remember visual inspection is weak, though, and that justifies a greater MOS and ultimately my recommendation to SELL.

MDT is a BUY under $70/share. With a forecast high price ~$95, my personal TAR criterion will be satisfied ~$48.

Categories: BetterInvesting® | Comments (0) | Permalink

ALGN Stock Study (5-8-24)

Posted by on May 24, 2024 at 06:38 | Last modified: May 9, 2024 10:32

I recently did a stock study on Align Technology Inc. (ALGN, $286.52). Previous studies are here and here.

CFRA writes:

     > Align Technology, Inc. (ALGN) is a global medical device company
     > engaged in the design, manufacture, and marketing of Invisalign
     > clear aligners and iTero intraoral scanners and services for
     > orthodontics, and restorative and aesthetic dentistry. ALGN
     > also provides exocad computer-aided design and computer-aided
     > manufacturing (“CAD/CAM”) software for dental laboratories and
     > dental practitioners. ALGN’s products are intended primarily
     > for the treatment of malocclusion or the misalignment of teeth.

Over the last 10 years, this medium-size company has posted annualized growth of 22.3% and 14.7% for sales and EPS (excluding COVID years ’20 and ’21 for the latter: upside outliers that otherwise boost EPS growth rate to 20.6%), respectively. Lines are mostly up, straight, and parallel except for a spike in ’20 EPS and ’22 EPS that drops off considerably.

Over the past decade, PTPM mostly leads peer and industry averages despite trending down from 25.0% (’14) to 16.6% (’23) with a last-5-year mean of 19.4%. ROE leads peer and industry averages despite falling from 19.7% (’14) to 11.7% (’23) with a last-5-year mean (excluding ’20) of 19.1%. Debt-to-Capital is far below peer and industry averages with a last-5-year mean of 3.4% (the company has no long-term debt per Value Line).

Value Line gives ALGN a Financial Strength rating of B++. M* gives a “Standard” rating for Capital Allocation and assigns a “Narrow” economic moat. Quick Ratio is 1.02.

With regard to sales growth:

I am forecasting below the range at 6.0% per year.

With regard to EPS growth:

I am forecasting below the long-term-estimate range (mean of five: 12.2%) at 7.0% per year. I will use ’23 EPS of $5.81 as the initial value rather than 2024 Q1 $6.07/share (annualized).

My Forecast High P/E is 43.0. Over the past decade, high P/E ranges from 36.8 in ’14 (excluding 24.3 in ’20) to 81.1 in ’18 (excluding upside outlier of 142 in ’22) with a last-5-year mean of 58.0 and a last-5-year-mean average P/E of 51.0. Albeit above my comfort zone, my forecast would be the lowest since ’16 (43.8).

My Forecast Low P/E is 30.0. Over the past decade, low P/E ranges from 24.4 in ’14 (excluding 5.7 in ’20) to 38.3 in ’18 (excluding 51.0 in ’21) with a last-5-year average of 32.8. My forecast would be the lowest since ’16 [24.6 (excluding ’20)].

My Low Stock Price Forecast (LSPF) is $200.50. Default based on $5.81/share would be $174.30: 39.2% less than previous close and 1.1% less than the 52-week low. Because this seems unreasonably low, I will discount previous close by 30.0%.

These inputs land ALGN in the HOLD zone with a U/D ratio of 0.7. Total Annualized Return (TAR) is 4.1%.

PAR (using Forecast Average—not High—P/E) of 0.7% is less than the current yield on T-bills. If a healthy margin of safety (MOS) anchors this study, then I can proceed based on TAR instead (still much lower than I seek for a medium-size company).

To assess MOS, I compare my inputs with those of Member Sentiment (MS). Based on only 47 studies done in the past 90 days (my study and 17 other outliers excluded), averages (lower of mean/median) for projected sales growth, projected EPS growth, Forecast High P/E, and Forecast Low P/E are 7.8%, 16.5%, 49.0, and 28.1, respectively. I am lower on all but the latter. Value Line projects a future average annual P/E of 26.5 that is much lower than MS (38.6) and mine (36.5).

MS high / low EPS are $12.92 / $5.82 versus my $8.15 / $5.81 (per share). My high EPS is lower due to a lower growth rate. Value Line’s high EPS of $14.85 is much greater than both (thereby offsetting the 26.5 from above).

MS LSPF of $169.90 implies a Forecast Low P/E of 29.2 versus the above-stated 28.1. MS LSPF is 4.1% greater than the default $5.81/share x 28.1 = $163.26 resulting in more aggressive zoning. MS LSPF is 15.3% less than mine, however.

TAR (over 15.0% preferred) is much less than MS 15.3%. I believe MOS to be robust in the current study.

With regard to valuation, PEG is 4.3 and 6.3 per Zacks and my projected P/E, respectively: significantly overvalued. Relative Value [(current P/E) / 5-year-mean average P/E] is slightly undervalued at 0.93.

This stock is up almost 48% in the last six months. Its longer-term appreciation potential has fallen accordingly. If not for its continued growth prospects, I would SELL.

ALGN is a BUY under $238/share. With a forecast high price ~$350, my personal TAR criterion will be satisfied ~$175.

Full disclaimer: I currently own shares of ALGN.

Categories: BetterInvesting® | Comments (0) | Permalink

RMD Stock Study (5-7-24)

Posted by on May 22, 2024 at 07:07 | Last modified: May 7, 2024 10:46

I recently did a stock study on ResMed Inc. (RMD) with a closing price of $216.94. The previous study is here.

M* writes:

     > ResMed is one of the largest respiratory care device companies
     > globally, primarily developing and supplying flow generators,
     > masks and accessories for the treatment of sleep apnea.
     > Increasing diagnosis of sleep apnea combined with ageing
     > populations and increasing prevalence of obesity is resulting
     > in a structurally growing market. The company earns roughly
     > two thirds of its revenue in the Americas and the balance
     > across other regions dominated by Europe, Japan and Australia.
     > Recent developments and acquisitions have focused on digital
     > health as ResMed is aiming to differentiate itself through
     > the provision of clinical data for use by the patient,
     > medical care advisor and payer in the out-of-hospital setting.

Over the past 10 years, this medium-size company has grown sales and earnings at annualized rates of 11.7% and 10.9%, respectively. Lines are mostly up, straight, and parallel except for EPS dips in ’17, ’18, and ’21. FY ends June 30.

Over the past decade, PTPM leads peer and industry averages while ranging from 19.9% in ’19 to 27.7% in ’14 with a last-5-year mean of 25.0%. ROE leads peer and industry averages while ranging from 15.1% in ’18 to 27.4% in ’20 with a last-5-year mean of 22.2%. Debt-to-Capital is lower than the industry and roughly even with peers while increasing from 14.6% in ’14 to 27.7% in ’23 with a last-5-year mean of 28.6%.

Value Line rates the company “A” for Financial Strength. M* rates the company “Exemplary” for Capital Allocation and assigns a “Narrow” economic moat. Quick Ratio is 1.3.

With regard to sales growth:

My 7.0% per year forecast is at the bottom of the range.

With regard to EPS growth:

My 9.0% per year forecast is below the long-term estimate range [mean of five: 11.9%]. I will use ’23 EPS of $6.09/share as the initial value rather than 2024 Q3 $6.51 (annualized).

My Forecast High P/E is 30.0. Over the past decade, high P/E trends up from 24.0 (’14) to 40.7 (’23) with a last-5-year mean of 52.7 and a last-5-year-mean average P/E of 44.1. I am near the bottom of the range [only ’14 and ’16 (25.8) are lower].

My Forecast Low P/E is 23.0. Over the past decade, low P/E trends up from 17.4 in ’14 to 33.2 in ’23 with a last-5-year mean of 35.6. My forecast would be the lowest value since 2016 (19.7).

My Low Stock Price Forecast (LSPF) of $140.10 is default based on $6.09/share initial value. This is 35.4% less than the previous closing price and 21.4% less than the 52-week low.

Over the past decade, Payout Ratio decreases from 41.8% in ’14 to 28.9% in ’23 with a last-5-year mean of 39.6%. I am forecasting below the range at 28.0%.

These inputs land RMD in the HOLD zone with a U/D ratio of 0.8. Total Annualized Return (TAR) is 6.3%.

PAR (using Forecast Average—not High—P/E) is less than the current yield on T-bills at 3.8%. If a healthy margin of safety (MOS) anchors this study, then I can proceed based on TAR instead.

To assess MOS, I compare my inputs with those of Member Sentiment (MS). Based on 222 studies done in the past 90 days (my study along with 81 other outliers excluded), averages (lower of mean/median) for projected sales growth, projected EPS growth, Forecast High P/E, Forecast Low P/E, and Payout Ratio are 7.4%, 10.0%, 36.8, 28.0, and 39.2%. I am lower across the board. Value Line’s future average annual P/E of 28.0 is lower than MS (32.4) but higher than mine (26.5).

MS high / low EPS are $9.81 / $6.05 versus my $9.37 / $6.09 (per share). My high EPS is less due to a lower growth rate. Both are less than Value Line high EPS of $10.00.

MS LSPF of $145.20 implies a Forecast Low P/E of 24.0 vs. the above-stated 28.0. MS LSPF is 14.3% less than the default $6.05/share * 28.0 = $169.40 resulting in more conservative zoning. MS LSPF remains 3.6% greater than mine.

TAR (over 15.0% preferred) is much less than MS 14.2%. I believe MOS to be robust in the current study.

With regard to valuation, PEG is 2.7 and 3.4 per Zacks and my projected P/E, respectfully: both overvalued. Relative Value [(current P/E) / 5-year-mean average P/E] is still cheap at 0.76.

While still within the stock price range of the last three years, RMD currently trades near its 2024 high.

RMD is a BUY under $175/share. With a forecast high price ~$280, my personal TAR criterion won’t be satisfied until ~$140.

Full disclaimer: I currently own shares of RMD.

Categories: BetterInvesting® | Comments (0) | Permalink

OZK Stock Study (5-6-24)

Posted by on May 20, 2024 at 07:17 | Last modified: May 6, 2024 10:43

I recently did a stock study on Bank OZK (OZK) with a closing price of $46.75. My previous study is here.

Value Line writes:

     > Bank OZK (formerly Bank of the Ozarks) is a bank holding company.
     > The company owns an Arkansas state chartered subsidiary bank, Bank
     > of the Ozarks, that conducts operations through 240 offices. Bank
     > OZK provides a range of retail and commercial banking services.
     > Deposit services includes: checking, savings, money market, time
     > deposit, and individual retirement accounts. Loan services include:
     > various types of real estate, consumer, commercial, industrial and
     > agricultural loans, and various leasing services. The company also
     > provides mortgage lending; treasury management services for
     > businesses, individuals and non-profit and governmental entities
     > including: wholesale lock-box services; remote deposit capture
     > services; trust and wealth management services for businesses,
     > individuals and non-profit and governmental entities; real estate
     > appraisals; ATMs; telephone banking; online and mobile banking
     > services; debit cards, gift cards, and safe deposit boxes.

Over the past 10 years, this medium-size company has grown sales and EPS at annualized rates of 14.8% and 12.3%, respectively. Lines are mostly up and parallel except for a sales dip in ’19 and EPS dips in ’18 and ’20.

Over the past decade, PTPM leads peer and industry averages while ranging from 38.2% in ’20 to 68.6% in ’21 with a last-5-year mean of 55.5%. ROE leads peer and industry averages ranging from 10.4% in ’19 (excluding 7.0% outlier in ’20) to 14.6% in ’23 with a last-5-year mean of 11.4%. Debt-to-Capital is much less than peer and industry averages ranging from 9.5% in ’17 to 22.0% in ’14 with a last-5-year mean of 18.7%.

Return on Average Assets (ROAA) has a last-5-year mean of 1.87%. Aside from 1.15% in ’20 (COVID-19), the lowest ROAA in the last 10 years is 1.85% in ’19. That is impressive!

Value Line gives a B+ grade for Financial Strength.

With regard to sales growth:

I am forecasting toward the lower end of the range at 3.0% per year.

With regard to EPS growth:

Despite being less than either long-term estimate (6.0% and 12.0% for a mean of 9.0%), I don’t consider my forecast overly conservative. It seems high relative to estimates for the next 2-3 years and plenty of room for error exists with only two longer-term estimates that currently exceed it.

I will use ’23 EPS of $5.87/share as the initial value.

My Forecast High P/E is 8.0. Over the past decade, high P/E trends down from 25.1 (’14) to 8.9 (’11) with a last-5-year mean of 11.1. The last-5-year-mean average P/E is 8.8. I am forecasting below the range.

My Forecast Low P/E is 6.0. Over the past decade, low P/E trends down from 18.1 (’14) to 5.2 (’23) with a last-5-year mean of 6.6. I am forecasting near the bottom of the range (only ’23 is lower).

My Low Stock Price Forecast (LSPF) of $35.20 is the default value based on $5.87/share. This is 24.7% less than the previous close and 14.7% greater than the 52-week low.

Over the past decade, Payout Ratio ranges from 21.2% in ’17 to 47.7% (upside outlier) in ’20 with a last-5-year mean (excluding the outlier) of 26.5%. I am forecasting below the range at 21.0%.

These inputs land OZK in the HOLD zone with a U/D ratio of 1.1. Total Annualized Return (TAR) is 7.7%.

PAR (using Forecast Average—not High—P/E) of 5.3% is comparable to the current yield on T-bills. If a healthy margin of safety (MOS) anchors this study, then I can proceed based on TAR 7.7% instead.

To assess MOS, I compare my inputs with those of Member Sentiment (MS). Based on only 16 studies done in the past 90 days (8 outliers including my own excluded), averages (lower of mean/median) for projected sales growth, projected EPS growth, Forecast High P/E, Forecast Low P/E, and Payout Ratio are 8.0%, 7.6%, 10.6, 6.5, and 28.5%, respectively. I am lower across the board. No 5-year P/E range is available for comparison.

MS high / low EPS are $8.48 / $5.45 versus my $7.49 / $5.87 (per share). My high EPS is lower due to a lower growth rate. No 5-year consensus estimate is available for comparison.

MS LSPF of $31.00 implies a Forecast Low P/E of 5.7 versus the above-stated 6.5. MS LSPF is 12.5% less than the default $5.45 share * 6.5 = $35.43 resulting in more conservative zoning. MS LSPF is also 11.9% less than mine.

TAR (over 15.0% preferred) is much less than MS 17.2%. Despite the small MS sample, I have forecasted conservatively at every turn. I believe MOS to be robust in the current study.

With regard to valuation, PEG is 1.5 (fairly valued) per my projected P/E. Relative Value [(current P/E) / 5-year-mean average P/E] is slightly undervalued at 0.91.

While ROAA is stellar for this bank, the stock has had quite a run and is now extended from a buy point.

OZK is a BUY under $41/share. With a forecast high price ~$60, my personal TAR criterion will be satisfied ~$30.

Categories: BetterInvesting® | Comments (0) | Permalink

VRSN Stock Study (5-3-24)

Posted by on May 16, 2024 at 07:11 | Last modified: May 3, 2024 10:54

I recently did a stock study on Verisign, Inc. (VRSN) with a closing price of $168.34.

M* writes:

     > Verisign is the sole authorized registry for several generic top-level
     > domains, including the widely utilized .com and .net top-level domains.
     > The company operates critical internet infrastructure to support the
     > domain name system, including operating two of the world’s 13 root
     > servers that are used to route internet traffic. In 2018, the firm
     > sold off its Security Services business, signaling a renewed focus
     > on the core registry business.

Over the last 10 years, this medium-size company has grown sales and earnings at annualized rates of 4.1% and 13.9%, respectively. Lines are mostly up, somewhat straight, and parallel/narrowing except for YOY EPS declines in ’21 and ’22.

Over the past decade, PTPM leads peer/industry averages while increasing from 47.8% (’14) to 65.4% (’23) with a last-5-year mean of 61.4%. ROE trails peer/industry averages and is negative throughout with a last-5-year mean of -49.1%. Debt-to-Capital is higher than peer/industry averages [and perhaps unacceptably high for some] with a last-5-year mean of 599%.

Despite what appears to be an upside-down balance sheet with Quick Ratio 0.77, Interest Coverage is 14.2. Value Line gives an “A” grade for Financial Strength and M* an “Exemplary” rating for Capital Allocation. Even CFRA, who has a SELL rating on the stock, writes: “VRSN maintains a healthy balance sheet of total cash and short-term investments of $924M, and nearly $1.8B in debt. Its closest debt maturity is April 2025 for $500M.”

M* assigns the company a “Wide” Economic Moat as a partial monopoly.

With regard to sales growth:

I am forecasting below the range at 4.0% per year.

With regard to EPS growth:

My 6.0% per year forecast is below the three-long-term-estimate range (mean 9.6%). My biggest concern is the lack of analyst coverage/estimates. Otherwise, I might feel comfortable going 1.0% higher. I will use ’23 EPS of $7.90/share as the initial value rather than 2024 Q1 EPS of $8.14 (annualized).

My Forecast High P/E is 25.0. Over the past decade, high P/E ranges from 25.0 in ’14 to 43.1 in ’19 with a last-5-year mean of 36.2 and a last-5-year-mean average P/E of 30.5. I am at the bottom of the range.

My Forecast Low P/E is 16.0. Over the past decade, low P/E trends up from 18.4 (’14) to 23.9 (’23) with a last-5-year mean of 24.8. I am below the range.

My Low Stock Price Forecast (LSPF) is the default of $126.40 based on $7.90/share initial value. This is 24.9% less than the previous close and 18.6% less than the 2022 low.

These inputs land VRSN in the HOLD zone with a U/D ratio of 2.5. Total Annualized Return (TAR) is 10.1%.

PAR (using Forecast Average—not High—P/E) is less than I seek for a medium-size company at 5.8%. If a healthy margin of safety (MOS) anchors this study, then I can proceed based on TAR instead.

To assess MOS, I compare my inputs with those of Member Sentiment (MS). Unfortunately, this stock has been largely overlooked by the community. Based on only seven studies done in the past 90 days (excluding two outliers including my own), averages (lower of mean/median) for projected sales growth, projected EPS growth, Forecast High P/E, and Forecast Low P/E are 6.0%, 8.6%, 30.0, and 23.3, respectively. I am lower across the board. Value Line projects a future average annual P/E of 24.0 that is lower than MS (26.7) and higher than mine (20.5).

MS high / low EPS are $11.99 / $7.71 versus my $10.89 / $7.90 (per share). My high EPS is lower due to a lower growth rate. Value Line’s high EPS of $12.80 is greater than both.

MS LSPF of $163.90 implies a Forecast Low P/E of 21.3 versus the above-stated 23.3. MS LSPF is 8.8% less than the default $7.71/share * 23.3 = $163.90, which results in more conservative zoning. MS LSPF is 29.7% greater than mine, however.

TAR (over 15.0% preferred) is much less than MS 14.4%. Despite the tiny MS sample, I attempt to forecast conservatively at every turn. Especially given the company’s consistent revenue model, I believe MOS to be robust in the current study.

With regard to valuation, PEG is 3.3 per my projected P/E: significantly overvalued. Relative Value [(current P/E) / 5-year-mean average P/E] is cheap at 0.68.

I won’t pound the table too hard because of the debt (much used to acquire treasury stock). What few analysts weigh in are also split with CFRA’s SELL, M* giving four stars, and Value Line claiming solid long-term potential. At the very least, I think the business model/monopoly is fascinating and theoretically able to justify M*’s “Wide” Economic Moat.

VRSN is a BUY under $162/share. With a forecast high price ~$272, my personal TAR criterion will be satisfied around $136.

Categories: BetterInvesting® | Comments (0) | Permalink

CPAY Stock Study (5-2-24)

Posted by on May 14, 2024 at 06:42 | Last modified: May 2, 2024 10:13

I recently did a stock study on Corpay, Inc. [CPAY (formerly FLT), $296.25]. Previous studies are here and here.

Value Line writes:

     > Corpay, Inc. (formerly FLEETCOR) is a leading independent provider of
     > fuel cards, and payment products and services throughout North America,
     > Latin America, and Europe. Its corporate charge cards cater to
     > commercial fleets, major oil companies, petroleum marketers, and
     > government entities. The company owns and operates proprietary
     > closed-loop networks electronically connected to merchants, through
     > which it captures and reports customized information.

Over the last 10 years, this medium-size company has grown sales and earnings at annualized rates of 11.3% and 14.5%, respectively. Lines are mostly up, straight, and parallel except for a sales decline in ’20 and EPS declines in ’15 and ’20.

Over the past decade, PTPM leads peer and industry averages while ranging from 31.5% in ’15 to 45.0% in ’18 with a last-5-year mean of 37.8%. ROE leads peer averages and tracks evenly with the industry while generally trending up from 24.9% (’14) to 31.2% (’23) with a last-5-year mean of 28.4%. Debt-to-Capital is higher than peer and industry averages while trending higher from 56.6% (’14) to 67.2% (’23) with a last-5-year mean of 64.5%.

Interest Coverage is 4.8 or 13.8 according to M* or Value Line, respectively. M* reports Quick Ratio as 0.52. Value Line gives a B++ grade for Financial Strength. CFRA writes: “We like CPAY’s balance sheet at 2.7x net debt-to-EBITDA, down from 3.3x in Q4 2022, with healthy liquidity of ~$2.2B.”

With regard to sales growth:

I am forecasting below the range at 8.0% per year.

With regard to EPS growth:

My 10.0% per year forecast is below the four-long-term-estimate range. Although most estimates have edged slightly lower since my previous stock study nine months ago, I have increased by 200 basis points and am still under the analyst mean of 14.3%. I will use ’23 EPS of $13.20/share as the initial value.

My Forecast High P/E is 21.0. Over the past decade, high P/E ranges from 21.4 (’22) to 43.0 (’15) with a last-5-year mean of 29.0 and a last-5-year-mean average P/E of 23.0. I am below the range.

My Forecast Low P/E is 13.0. Over the past decade, low P/E ranges from 13.0 (’22) to 34.9 (’15) with a last-5-year mean of 17.1. I am at the bottom of the range.

My Low Stock Price Forecast (LSPF) is $204.00. Default based on $13.20/share initial value seems unreasonably low at $171.60 (42.1% less than the previous close). I am using the 52-week low price instead (31.1% less).

These inputs land CPAY in the HOLD zone with a U/D ratio of 1.6. Total Annualized Return (TAR) is 8.5%.

PAR (using Forecast Average—not High—P/E) is less than the current yield on T-bills at 4.1%. If a healthy margin of safety (MOS) anchors this study, then I can proceed based on TAR instead.

To assess MOS, I compare my inputs with those of Member Sentiment (MS). Based on 136 studies done in the past 90 days (my study and 36 outliers excluded), averages (lower of mean/median) for projected sales growth, projected EPS growth, Forecast High P/E, and Forecast Low P/E are 9.4%, 11.9%, 24.7, and 16.8, respectively. I am lower across the board. Value Line projects a future average annual P/E of 16.0 that is lower than MS (20.8) and mine (17.0).

MS high / low EPS are $23.14 / $12.87 vs. my $21.26 / $13.20 (per share). My high EPS is lower due to a lower growth rate. Value Line’s high EPS of $34.00 is much higher than both.

MS LSPF of $202.40 implies a Forecast Low P/E of 15.7 vs. the above-stated 16.8. MS LSPF is 6.4% less than the default $12.87/share * 16.8 = $216.22, which results in more conservative zoning. MS LSPF is also 0.8% less than mine.

TAR (over 15.0% preferred) is much less than MS 14.3%. MOS backing the current study seems robust.

With regard to valuation, PEG is 1.1 and 2.0 per Zacks and my projected P/E, respectively: the latter is overvalued. Relative Value [(current P/E) / 5-year-mean average P/E] is fair at 0.97.

Up ~46% over the past year, the stock has been on a roll. These are tough stocks to buy because they are often well extended from a buy point. More than anything else, I think that is taking place here.

CPAY is a BUY under $264/share. With a forecast high price ~$446, my TAR criterion will be met ~$223.

Categories: BetterInvesting® | Comments (0) | Permalink

Are Stock Studies Helpful to [Prospective] BI Members?

Posted by on May 11, 2024 at 09:10 | Last modified: July 4, 2024 08:36

In a relatively short period of time (since www.optionfanatic.com is well over 12 years old), over 15% of my blog content is now BetterInvesting (BI) stock studies. While I have an idea whether this is helping anybody, I am more curious about whether this can help anybody.

Posting studies in the blog certainly helps me by keeping me structured and holding me accountable. When I stopped posting studies, I stopped doing studies for about five months (see here).

Learning how to size up and analyze a stock was the main reason I joined BI. Mission accomplished: 220 (and counting) posted right here are testament to that fact.

Option Fanatic is primarily for personal use only as part and parcel of my trading business. I leave it public, however, and welcome anyone to read it. Occasionally, I get comments or emails. I am more than happy if the blog can help anybody else.

Without blog publicity/advertising, I doubt many people are reading. From time to time I have looked at the analytics and not seen large numbers. I have lots of quality content but a helping hand may be needed for it to make an impact: some instruction on adapting what works for me with what can work for them and how they can make that happen.

I doubt stock studies posted here are helping others for two reasons. First, not advertising my blog prevents others from discovering it. Second, these studies are incomplete. BI members will understand most of what I write, but graphical/tabular data presentation (completing the study as a First Cut) would greatly benefit non-members and is not included.

This brings me to the next question: can these studies help anybody? The studies are publicity to demonstrate the BI stock study methodology. The BI website, www.betterinvesting.org, includes [complete] First Cuts, though, and anyone can get a 90-day free trial for that. All studies posted here are also submitted to the BI website as First Cuts.

One thing that cannot be done on the BI website is sorting by author. All my studies may be seen on my blog. A particular stock must be known/selected to find my respective First Cut(s) on the BI website. The BI website archives everyone’s First Cut submissions, though. I strongly encourage reading a variety of members because different nuances and tweaks to the analytical process will resonate with different investors.

Studies posted on my blog can be useful for non-members to get a sense of the BI process without giving personal details. I am sometimes wary of free trials if I have to submit an address, phone number, email, or credit card. If avoidance of the latter enables my blog to facilitate an introduction to BetterInvesting, then so much the better!

Just some random thoughts on what started out as a cloudy and rainy day in South Florida…

Categories: BetterInvesting® | Comments (0) | Permalink

CTSH Stock Study (5-1-24)

Posted by on May 10, 2024 at 06:58 | Last modified: May 1, 2024 11:40

I recently did a stock study on Cognizant Technology Solns Corp. (CTSH, $65.68). Previous studies are here, here, and here.

M* writes:

     > Cognizant is a global IT services provider, offering consulting and
     > outsourcing services to some of the world’s largest enterprises spanning
     > the financial services, media and communications, healthcare, natural
     > resources, and consumer products industries. Cognizant employs nearly
     > 300,000 people globally, roughly 70% of whom are in India, although
     > the company’s headquarters are in Teaneck, New Jersey.

Over the past 10 years, this large-size company has grown sales and EPS at annualized rates of 6.8% and 6.9%. Visual inspection is mediocre with sales dips in ’20 and ’23 along with EPS rockiness from declines in ’16, ’17, ’19, ’20, and ’23.

Over the past decade, PTPM leads peer and industry averages despite trending down from 18.7% (’14) to 14.4% (’23) with a last-5-year mean of 14.6%. ROE trails peer and industry averages, ranging from 12.2% in ’20 to 19.4% in ’14 with a last-5-year mean of 16.5%. Debt-to-Capital is much less than peer and industry averages while declining from 17.5% (’14) to 9.0% (’23) with a last-5-year mean of 11.9%.

Quick Ratio is 1.9 and Interest Coverage is 69.0. M* gives a “Standard” rating for Capital Allocation while Value Line gives an “A+” grade for Financial Strength.

With regard to sales growth:

I am forecasting below both long-term estimates at 5.0% per year.

With regard to EPS growth:

My 6.0% forecast is below the long-term-estimate range (mean of five: 9.0%). Initial value will be ’23 EPS of $4.21/share.

My Forecast High P/E is 19.0. Over the past decade, high P/E trends down from 23.4 (’14) to 18.3 (’23) with a last-5-year mean of 23.3 and a last-5-year-mean average P/E of 19.1. I am forecasting near the bottom of the range (only ’23 is less).

My Forecast Low P/E is 12.0. Over the past decade, low P/E trends down from 17.7 (’14) to 13.4 (’23) with a last-5-year mean of 14.8. I am forecasting near the bottom of the range [only ’22 is less (11.6)].

My Low Stock Price Forecast (LSPF) of $50.50 is default based on initial value of $4.21/share. This is 23.1% less than the previous close and 13.7% less than the 52-week low.

Since a dividend is first issued in 2017, Payout Ratio ranges from 17.8% in ’17 to 34.2% in ’20 with a last-5-year mean of 26.9%. I am forecasting below the range at 17.0%.

These inputs land CTSH in the HOLD zone with a U/D ratio of 2.7. Total Annualized Return (TAR) is 11.2%.

PAR (using Forecast Average—not High—P/E) is 7.0%, which is less than I seek in a large-size company. If a healthy margin of safety (MOS) anchors this study, then I can proceed based on TAR instead.

To assess MOS, I compare my inputs with those of Member Sentiment (MS). Based on 94 studies done in the past 90 days (my study and 41 outliers excluded), averages (lower of mean/median) for projected sales growth, projected EPS growth, Forecast High P/E, Forecast Low P/E, and Payout Ratio are 4.1%, 6.8%, 20.6, 14.8, and 24.8%. I am lower on all but sales growth. Value Line projects a future average annual P/E of 17.0, which is lower than MS (17.7) and higher than mine (15.5).

MS high / low EPS are $5.89 / $4.20 versus my $5.63 / $4.21 (per share). My high EPS is lower due to a lower growth rate. Value Line’s high EPS is much higher than both at $7.00.

MS LSPF of $54.70 implies a Forecast Low P/E of 13.0 vs. the above-stated 14.8. MS LSPF is 12.0% less than the default $4.20/share * 14.8 = $62.16, which results in more conservative zoning. MS LSPF remains 8.3% greater than mine.

TAR (over 15.0% preferred) is very close to MS 11.8%. MOS seems small in the current study, which is unusual for me.

With regard to valuation, PEG is 1.5 and 2.5 per Zacks and my projected P/E, respectively: latter is overvalued. Relative Value [(current P/E) / 5-year-mean average P/E] is slightly cheap at 0.82.

One thing that jumps out is increasing analyst estimates from my previous First Cut nine months ago. Both Value Line and M* expect growth to increase in ’25 and beyond. This could bode well for my MOS although with the current increases I have also increased my P/E range. I’ll need to keep judgments fixed to bolster MOS.

CTSH is a BUY under $64/share. With a forecast high price of $107, my TAR criterion won’t be met until $53.50.

Categories: BetterInvesting® | Comments (0) | Permalink
Older Entries